TABLE 1.
Clinical efficacy of RDV, by major clinical trial
| Study (reference) | Comparison | n | Double blind? | Controlled? | Primary endpoint | Outcome |
|---|---|---|---|---|---|---|
| Goldman et al. (7) | 5- vs 10-day RDV in severe COVID-19 | 397 | No | No | Clinical status at day 14 by 7-point ordinal scale | No statistically significant difference between treatment groups |
| Wang et al. (2) | RDV vs placebo in severe COVID-19 | 237 | Yes | Yes (placebo) | Time to clinical improvement up to day 28 | No statistically significant difference between placebo and RDV groups |
| Beigel et al. (4) | RDV vs placebo in severe COVID-19 | 1,062 | Yes | Yes (placebo) | Time to recovery, discharge from hospital vs. hospitalization | Shortened median time to recovery in RDV vs placebo groups (10 vs 15 days) |
| Spinner et al. (8) | 5- vs 10-day RDV vs SOCa in moderate COVID-19 | 596 | No | Yes (SOC) | Clinical status at day 11 by 7-point ordinal scale | 5-Day RDV had statistically significant higher odds of better clinical status |
| WHO Solidarity Trial Consortium (3) | One of trial drug regimens (including RDV) vs local SOC in severe COVID-19 | 2,750 | No | Yes (local SOC) | In-hospital mortality | No effect on mortality for patients hospitalized with COVID-19 |
a
SOC, standard of care.